{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:30:22Z","timestamp":1785198622058,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We aimed to retrospectively analyze the risk factors of a continuous dienogest (DNG) therapy for serious unpredictable bleeding in patients with symptomatic adenomyosis. This is a retrospective study based on data extracted from medical records of 84 women treated with 2\u2009mg of DNG orally each day between 2008 and 2017. 47 subjects were excluded from the original analyses due to an inadequate subcategorization into subtype I and subtype II and a lack of hemoglobin levels. The influence of various independent variables on serious unpredictable bleeding was assessed. Of the 37 eligible patients who received the continuous DNG therapy, 14 patients experienced serious unpredictable bleeding. Univariate analysis revealed that the serious bleeding group had subtype I adenomyosis (P\u2009=\u20090.027). There was no correlation between age, parity, minimum hemoglobin level before treatment, previous endometrial curettage, and duration of DNG administration, or uterine or adenomyosis size and the serious bleeding. A DNG-related serious unpredictable bleeding is associated with the structural type of adenomyosis (subtype I) in patients with symptomatic adenomyosis.<\/jats:p>","DOI":"10.1038\/s41598-019-54096-z","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T11:02:46Z","timestamp":1574852566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Subtype I (intrinsic) adenomyosis is an independent risk factor for dienogest-related serious unpredictable bleeding in patients with symptomatic adenomyosis"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4323-5470","authenticated-orcid":false,"given":"Sho","family":"Matsubara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Akinishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Nagayasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Iwai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Niiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Tanase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,27]]},"reference":[{"key":"54096_CR1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.bpobgyn.2006.01.010","volume":"20","author":"J Kitawaki","year":"2006","unstructured":"Kitawaki, J. Adenomyosis: the pathophysiology of an oestrogen-dependent disease. Pract Res Clin Obstet Gynaecol 20, 493\u2013502 (2006).","journal-title":"Pract Res Clin Obstet Gynaecol"},{"issue":"2","key":"54096_CR2","doi-asserted-by":"publisher","first-page":"114. e1","DOI":"10.1016\/j.ajog.2012.06.027","volume":"207","author":"Y Kishi","year":"2012","unstructured":"Kishi, Y. et al. Four subtypes of adenomyosis assessed by magnetic resonance imaging and their specification. Am J Obstet Gynecol 207(2), 114. e1\u20137 (2012).","journal-title":"Am J Obstet Gynecol"},{"key":"54096_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jmig.2011.04.004","volume":"18","author":"L Garcia","year":"2011","unstructured":"Garcia, L. & Isaacson, K. Adenomyosis: review of the literature. J Minim Invasive Gynecol 18, 428\u2013437 (2011).","journal-title":"J Minim Invasive Gynecol"},{"issue":"2018","key":"54096_CR4","doi-asserted-by":"publisher","first-page":"6832685","DOI":"10.1155\/2018\/6832685","volume":"15","author":"JJ Li","year":"2018","unstructured":"Li, J. J. et al. The Investigation and Management of Adenomyosis in Women Who Wish to Improve or Preserve Fertility. Biomed Res Int. 15(2018), 6832685, https:\/\/doi.org\/10.1155\/2018\/6832685 (2018).","journal-title":"Biomed Res Int."},{"key":"54096_CR5","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1111\/jog.13406","volume":"43","author":"Y Osuga","year":"2017","unstructured":"Osuga, Y., Watanabe, M. & Hagino, A. Long-term use of dienogest in the treatment of painful symptoms in adenomyosis. J Obstet Gynaecol Res 43, 1441\u20131448 (2017).","journal-title":"J Obstet Gynaecol Res"},{"issue":"16","key":"54096_CR6","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.2165\/11206320-000000000-00000","volume":"70","author":"PL McCormack","year":"2010","unstructured":"McCormack, P. L. Dienogest: a review of its use in the treatment of endometriosis. Drugs 70(16), 2073\u20132088 (2010).","journal-title":"Drugs"},{"key":"54096_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.maturitas.2012.01.018","volume":"71","author":"X Ruan","year":"2012","unstructured":"Ruan, X., Seeger, H. & Mueck, A. O. The pharmacology of dienogest. Maturitas 71, 337\u2013344 (2012).","journal-title":"Maturitas"},{"key":"54096_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.fertnstert.2017.07.021","volume":"108","author":"Y Osuga","year":"2017","unstructured":"Osuga, Y., Fujimoto-Okabe, H. & Hagino, A. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study. Fertil Steril 108, 673\u2013678 (2017).","journal-title":"Fertil Steril"},{"key":"54096_CR9","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/humrep\/dep437","volume":"25","author":"KN Khan","year":"2010","unstructured":"Khan, K. N. et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod 25, 642\u2013653 (2010).","journal-title":"Hum Reprod"},{"issue":"4","key":"54096_CR10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/j.1447-0756.2011.01778.x","volume":"38","author":"C Nagata","year":"2012","unstructured":"Nagata, C. et al. Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest. J Obstet Gynaecol Res. 38(4), 639\u201344 (2012).","journal-title":"J Obstet Gynaecol Res."},{"key":"54096_CR11","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/jog.13674","volume":"44","author":"K Neriishi","year":"2018","unstructured":"Neriishi, K. et al. Long-term dienogest administration in patients with symptomatic adenomyosis. J Obstet Gynaecol Res 44, 1439\u20131444 (2018).","journal-title":"J Obstet Gynaecol Res"},{"key":"54096_CR12","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/bjh.12447","volume":"162","author":"M Pai","year":"2013","unstructured":"Pai, M., Chan, A. & Barr, R. How I manage heavy menstrual bleeding. Br J Haematol 162, 721\u2013729 (2013).","journal-title":"Br J Haematol"},{"key":"54096_CR13","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s13244-017-0576-z","volume":"8","author":"L Agostinho","year":"2017","unstructured":"Agostinho, L. et al. MRI for adenomyosis: a pictorial review. Insights Imaging 8, 549\u2013556 (2017).","journal-title":"Insights Imaging"},{"key":"54096_CR14","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1210\/jc.2006-0724","volume":"91","author":"M Hickey","year":"2006","unstructured":"Hickey, M. et al. Long-term progestin-only contraceptives result in reduced endometrial blood flow and oxidative stress. J Clin Endocrinol Metab 91, 3633\u20133638 (2006).","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"54096_CR15","first-page":"48","volume":"35","author":"T Cirpan","year":"2008","unstructured":"Cirpan, T. et al. Clinical symptoms and histopathological findings in subjects with adenomyosis uteri. Clin Exp Obstet Gynecol. 35(1), 48\u201353 (2008).","journal-title":"Clin Exp Obstet Gynecol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54096-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54096-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54096-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:38:12Z","timestamp":1671295092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54096-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,27]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["54096"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-54096-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,27]]},"assertion":[{"value":"17 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17654"}}